Illumina partners with customers to ensure data security At Illumina, we are proud of our track record of producing high-quality instruments and software suites that meet the changing needs of our diverse customer base. As part of that commitment to quality, we make ongoing efforts to assess our software for potential vulnerabilities and exposures. Most recently, we internally identified a vulnerability affecting Universal Copy Service (UCS), a proprietary software present on certain Illumina instruments. Upon identifying this vulnerability, our team worked diligently to develop mitigations to protect our instruments and customers. We then contacted and worked in close partnership with regulators and customers to address the issue with a simple software update at no cost, requiring little to no downtime for most. Illumina is committed to identifying and appropriately addressing potential vulnerabilities as part of our commitment to delivering quality products and ensuring data security. Regardless of what types of Illumina instruments or software our customers use, they can be assured that we keep the quality and security of our products of greatest importance. We are grateful to our customers for their partnership, and we will continue to proactively work with them to address any potential future concerns.
Alex Aravanis MD PhD’s Post
More Relevant Posts
-
I'm excited to announce the launch of Moonwalk Biosciences, a genomic medicine company pioneering precision epigenetic medicines, with $57 million in financing from Alpha Wave Ventures, ARCH Venture Partners, Future Ventures, GV, Khosla Ventures and YK Bioventures. The financing will support continued advancement of Moonwalk’s epigenetic profiling and engineering technology platform and progress its pipeline of epigenetic therapeutics towards the clinic. By targeting the epigenetic code – the software of the genome – Moonwalk aims to reprogram cells to their healthy state, fundamentally enabling a new approach to how therapies are discovered and developed. Moonwalk is the first company that couples an epigenetic discovery platform with precise engineering – opening up the epigenome as a new target space for complex diseases. Learn more here: https://moonwalk.bio/
This content isn’t available here
Access this content and more in the LinkedIn app
-
Exciting new research shared at ASCO last month supports comprehensive genomic profiling #CGP over single-gene testing as a starting point in treating non-small cell #lungcancer. Thank you to Phillip G. Febbo, MD, Vivek Subbiah, MD, and Prasanth Reddy MD, MPH, FACP for sharing their insights on the changing oncology landscape.
Physician Scientist and Leader | Chief Scientific Officer and Chief Medical Officer @ Veracyte
Cancer patients deserve the best care possible in order to have the best outcomes possible. During this year’s ASCO’s Annual Meeting, I sat down with Drs. Vivek Subbiah, MD and Prasanth Reddy MD, MPH, FACP to discuss a study that compared the results from single gene tests to comprehensive genomic profiling. Too often, focused tests deprive patients of valuable information about their tumors. This study, and other evidence, has shown that comprehensive testing provides better clinical insights to guide care. The next step will be to ensure all patients have access to primary CGP. Watch the full conversation below.
Illumina Oncology: ASCO Fireside Chat with Chief Medical Officer Phil Febbo
https://www.youtube.com/
-
Today we launched DRAGEN v4.2, our most comprehensive and accurate secondary analysis tool to date. Congratulations to the many team members at Illumina who worked on this latest update. Read more about the new targeted callers, machine learning algorithm, and improved accuracy across ethnically diverse samples in v4.2: https://lnkd.in/ggQdsvcm
-
-
Illumina’s Accelerator program for seed-stage companies helped launch 74 companies and attracted more than $1.2B in third party investments over 15 funding cycles. Based on this legacy, we believe the time is right to evolve the Accelerator program by partnering with Illumina Ventures in order to create an even bigger impact on the genomics start-up industry. Congratulations to Illumina Ventures Labs!
Announcing the launch of Illumina Ventures Labs! Building on the foundation of the Illumina Accelerator program, Illumina Ventures Labs will operate and provide access to fully equipped genomics labs in the US and the UK, mentorship, and seed financing to attract a broad range of genomics related start-ups. “The program will give early-stage companies a jump-start and accelerate timelines to the next value inflection point while providing additional investment opportunities for our fund,” said Nick Naclerio, Founding Partner. Read the full press release: https://lnkd.in/gUmdPjm7 #innovation #biotech #lifescience #genomics #startups
-
I'm proud of our team’s work on NovaSeq X, XLEAP-SBS Chemistry, and lyophilized reagents - helping sustainably accelerate access to genomics around the world.
In celebration of #WorldEnvironmentDay, we’re excited to share our new 2022 Corporate Social Responsibility (CSR) impact report and some of key accomplishments including: ✅ 100% electric consumption from renewable sources ✅ 61% climate impact reduction with NovaSeq™ X reagents ✅ 30% packaging reduction since 2019 ✅ 64% landfill diversion ✅ 9% reduction of water intensity year over year Learn more how we’re unlocking the power of genomics to positively impact the world and shape a more sustainable and equitable future for all: https://bit.ly/3IRaSMQ
-
Learn more about how Illumina’s PrimateAI-3D algorithm uses rare variant data to shed light on common diseases such as high cholesterol and cardiovascular disease and identify those at highest risk based on polygenic risk scores. https://lnkd.in/dMNt7Tbv
-
-
The groundbreaking genome research published last week in Science Magazine will enable conservationists to better understand and potentially slow the patterns of extinction among endangered primates. Learn more about the #WGS study of 809 individuals from 233 different primate species and what genetic mutations tell us about our closest living relatives. https://lnkd.in/gF-2Tgay
-
